Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics Inc. is poised for significant financial growth, with projections indicating risk-adjusted sales increasing to $171 million in 2026 and reaching a peak of $1.9 billion by 2031. The anticipated market penetration for relacorilant in ovarian cancer has increased to 25%, reflecting confidence in its clinical data, particularly following positive survival outcomes from the pivotal MIRASOL trial. Additionally, the strategic plan to launch relacorilant with a dedicated oncology sales force underscores the potential for commercial success, particularly as the company prepares for an upcoming pivotal decision on approval in July 2026.

Bears say

Corcept Therapeutics Inc is facing a negative outlook due to multiple factors reflected in its financial reports, primarily stemming from the Complete Response Letter (CRL) for its relacorilant drug, which is crucial for treating Cushing's syndrome, leading to significant drops in share price. The revisions in the financial model have resulted in a decrease of the 12-month price target to $90 per diluted share from $145, indicating diminished expectations for revenue growth as the delayed launch affects potential market entry timelines. Additionally, anticipated pricing pressure from payers may further negatively impact sales of Korlym, worsening the company’s financial projections and investor sentiment.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.